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Efforts to both characterize and eradicate the HIV reservoir have been limited by the 
rarity of latently infected cells and the absence of a specific denoting biomarker. CD32a 
(FcγRIIa) has been proposed to be a marker for an enriched CD4 T cell HIV reservoir, 
but this finding remains controversial. Here, we explore the expression of CD32 on 
CD3+CD4+ cells in participants from two primary HIV infection studies and identify at 
least three distinct phenotypes (CD32low, CD32+CD14+, and CD32high). Of note, CD4 
negative enrichment kits remove the majority of CD4+CD32+ T cells, potentially skew-
ing subsequent analyses if used. CD32high CD4 T  cells had higher levels of HLA-DR 
and HIV co-receptor expression than other subsets, compatible with their being more 
susceptible to infection. Surprisingly, they also expressed high levels of CD20, TCRαβ, 
IgD, and IgM (but not IgG), markers for both T cells and naïve B cells. Compared with 
other populations, CD32low cells had a more differentiated memory phenotype and high 
levels of immune checkpoint receptors, programmed death receptor-1 (PD-1), Tim-3, 
and TIGIT. Within all three CD3+CD4+CD32+ phenotypes, cells could be identified in 
infected participants, which contained HIV DNA. CD32 expression on CD4 T cells did 
not correlate with HIV DNA or cell-associated HIV RNA (both surrogate measures of 
overall reservoir size) or predict time to rebound viremia following treatment interruption, 
suggesting that it is not a dominant biomarker for HIV persistence. Our data suggest 
that while CD32+ T cells can be infected with HIV, CD32 is not a specific marker of the 
reservoir although it might identify a population of HIV enriched cells in certain situations.
Keywords: hiV, reservoir, cD32, primary hiV infection, hiV Dna
inTrODUcTiOn
A cure for HIV infection is contingent on targeting and neutralizing latently infected cells that persist 
despite effective antiretroviral therapy (ART). These cells are predominantly resting memory CD4 
T cells containing transcriptionally silent, integrated proviral HIV DNA. Activation of these cells 
results in HIV production and disease progression in the absence of ART. Latently infected cells 
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are extremely rare (0.0001–0.1% of CD4 T cells), complicating 
their study. Accordingly, there has been a research effort to 
identify cell surface markers that identify latently infected cells 
to facilitate their characterization and targeting. For example, 
immune checkpoint receptors (ICRs) (1) such as programmed 
death receptor-1 (PD-1), T cell immunoglobulin (Ig) and mucin 
domain-containing molecule (Tim)-3, and T cell immunorecep-
tor with Ig and ITIM domains (TIGIT) are associated with an 
exhausted effector state (2–5), and their expression correlates 
with HIV disease progression and viral rebound following treat-
ment interruption (TI) (4, 6, 7). ICRs have been reported to be 
highly expressed on cells comprising the HIV reservoir (8, 9), but 
are not discriminatory.
CD32a (FcγRIIa)—a low-affinity IgG receptor expressed on 
myeloid cells and granulocytes (10), has been proposed as a sur-
face marker for latent HIV infection (11). While this finding is of 
extremely high interest, the expression of CD32 on CD4 T cells 
remains controversial, and a role for low-affinity Fc receptors 
on CD4 T cells has not been well-established (12–14). Although 
CD4 T cells are generally not considered to express CD32, expres-
sion may be induced by activation in vitro (15, 16). Expression 
of CD32b on memory CD8 T cells in murine infection models 
is associated with reduced cytotoxicity and expansion, revers-
ible on CD32b blockade (17). This has interesting parallels with 
other co-inhibitory pathways, raising the possibility that CD32 
isoforms may have a similar regulatory role on activated, antigen 
experienced CD4 T cells.
Here, we investigate CD32 expression on CD3+CD4+ cells and 
identify distinct populations that express this marker. We also char-
acterize CD32-expressing CD4 T cells in the blood of individuals 
treated during primary HIV infection (PHI) [a group of interest 
due to an association with post treatment virological remission 
and a more labile reservoir (18–20)] and explore associations with 
overall reservoir size, cell phenotype, and clinical progression.
MaTerials anD MeThODs
Participants
Participants with PHI were recruited as part of the HEATHER 
(HIV Reservoir targeting with Early Antiretroviral Therapy) 
cohort. PHI was identified through one of the following criteria: 
(a) HIV-1 positive antibody test within 6  months of a HIV-1 
negative antibody test, (b) HIV-1 antibody negative with posi-
tive PCR (or positive p24 Ag or viral load detectable), (c) RITA 
(recent incident assay test algorithm) assay result consistent with 
recent infection, (d) equivocal HIV-1 antibody test supported by 
a repeat test within 2 weeks showing a rising optical density, and 
(e) having clinical manifestations of symptomatic HIV serocon-
version illness supported by antigen positivity. For inclusion in 
the cohort, participants with identified PHI commenced ART 
within 3 months of diagnosis and did not have co-infection with 
hepatitis B or C. Date of seroconversion was estimated as the 
midpoint of the dates of the most recent negative or equivocal 
test and positive test (criteria a and d above), the date of the test 
(b and e) or 120 days before the test date (c, the recency period 
of this assay). For our study, cryopreserved peripheral blood 
mononuclear cells (PBMCs) were used from the closest pre-
therapy sample to seroconversion (baseline) and from a sample 
9–15 months after commencement of ART (1 year).
Time to rebound analyses was conducted with a subset of par-
ticipants from the SPARTAC (Short Pulse Antiretroviral Therapy at 
HIV Seroconversion) trial (EudraCT Number: 2004-000446-20). 
This was a multicenter, randomized controlled trial of short course 
ART during PHI, the full design of which is described elsewhere 
(21). The criteria used to define PHI in this trial are similar to 
above. In brief, this trial enrolled adults with PHI from 25 sites in 
Australia, Brazil, Ireland, Italy, South Africa, Spain, Uganda, and the 
UK. Participants with PHI were randomized to receive no immedi-
ate ART (standard of care), 12 or 48 weeks of ART, after which 
they underwent a TI. The primary trial endpoint was a composite 
of CD4 T cell count less than 350 cells/μL or the initiation of long-
term ART for any reason. Cryopreserved PBMCs were used from 
participants who received 48 weeks of ART and were virologically 
suppressed to <400 copies/mL at the time of TI. Participants were 
included based on sample availability at the time of TI, and date of 
seroconversion was estimated as calculated previously (7).
Flow cytometry and cell sorting
Cryopreserved PBMCs were thawed in RPMI-1640 medium 
supplemented with 10% FBS, l-glutamine, penicillin, and 
streptomycin (R10) containing 2.7  Kunitz units/mL of DNAse 
(Qiagen). For analysis of memory phenotype and ICR expression, 
cells were stained in BD Horizon Brilliant Stain Buffer (BD) con-
taining all antibodies and Live/Dead Near IR at 1 in 300 dilution 
(Life Technologies) at 4°C for 30 min. PBMCs were stained with 
the following antibodies: CD32 PE-Cy7 (FUN-2), CD3 Brilliant 
Violet (BV) 570 (UCHT1), CCR7 Pacific Blue (G043H7), CD27 
AlexaFluor700 (M-5271) (all BioLegend), CD4 BV605 (RPA-T4), 
CD8 BV650 (RPA-T8) (BD), PD-1 PE-eFluor 610 (eBioJ105), 
CD45RA FITC (HI100), TIGIT PerCP-eFluor710 (MBSA43) (all 
eBioscience), and Tim-3 PE (344823) (R&D). Isotype controls 
for CD32 were prepared using an irrelevant IgG2bκ antibody 
(MPC-11) (BioLegend). For time to rebound analyses, cells were 
stained as above in PBS with 5% FBS and 1 mM EDTA (FACS 
buffer) containing Live/Dead Near IR, CD32 PE-Cy7, PD-1 
PE-eFluor610, TIGIT PerCP-eFluor710 as well as the following 
antibodies: CD3 FITC (UCHT1) (BioLegend) and CD4 eFluor450 
(OKT4) (eBioscience). For measurement of HLA-DR expression, 
cells were stained for 20 min at room temperature with LiveDead 
Near IR and the following antibodies: CD3 BV570, CD4 BV605, 
CD8 BV650, CD32 PE (FUN-2) (BioLegend) and HLA-DR 
AlexaFluor700 (MAB) (BD). Samples for HIV co-receptor stains 
were stained with LiveDead Near IR, CD32 PE-Cy7, CD3 FITC, 
and CD4 eFluor450. Following this, cells were incubated at 37°C 
for 20  min with anti-CCR5 PE (C57BL/6) (BD) or at 4°C for 
30 min with anti-CXCR4 APC (12G5) (Miltenyi).
For measurement of lineage marker expression on CD32-
expressing CD4 T cells, PBMCs were stained as above in R10 with 
antibodies as listed in Panels 1–6 below. A CD32 isotype control 
was used as above, and gates for lineage markers were determined 
using a fluorescence minus one or the positive population from 
bulk PBMC.
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Panel 1—CD11b, CD16, CD19, CD20, CD123, and TCRγδ 
staining. PBMCs were stained with LiveDead Near IR, 
CD3 AlexaFluor700 (UCHT1), CD4 APC (RPA-T4) (both 
BioLegend), CD32 PE-Cy7, CD14 VioBlue (TUK4) (Miltenyi), 
either CD11b FITC (M1/70.15.11.5) (Miltenyi), CD16 FITC 
(CB16) (eBioscience), CD19 FITC (LT19) (Miltenyi), CD20 
FITC (2H7) (BioLegend), CD123 PE (9F5) (BD Bioscience) or 
TCRγδ PE (11F2) (Miltenyi).
Panel 2—CD8, CD15, CD56 staining. PBMCs were stained 
with LiveDead Near IR, CD3 AlexaFluor700, CD4 APC, CD32 
PE-Cy7, and CD14 FITC (HCD14) (BioLegend) and CD8 
eFluor450 (OKT8), CD15 Pacific Blue (W6D3), or CD56 BV421 
(HCD56) (all BioLegend).
Panel 3—CD235a staining. PBMCs were stained with Fixable 
Viability Dye eFluor 506 (eBioscience), CD3 FITC, CD4 APC, 
CD32 PE-Cy7, CD14 VioBlue, and CD235a APC-Cy7 (HI264) 
(BioLegend).
Panel 4—CD36 staining. PBMCs were stained with LiveDead 
Near IR, CD3 FITC, CD32 PE-Cy7, CD4 AlexaFluor700 
(SK3) (BioLegend), CD14 VioBlue, and CD36 APC (AC106) 
(Miltenyi).
Panel 5—TCR αβ staining. PBMCs were stained with LiveDead 
Near IR, CD3 FITC, CD4 APC, CD32 PE, and CD14 VioBlue. 
Cells were then permeabilized using BD FACS Permeabilizing 
solution 2 as per the manufacturer’s protocol before washing 
and staining with TCR αβ PE-Cy7 (IP26) (BioLegend).
Panel 6—Ig staining. PBMCs were stained with LiveDead Near 
IR, CD3 AlexaFluor700, CD4 APC, CD32 PE-Cy7, CD14 
VioBlue, CD20 FITC and IgD PE (IA6-2), IgG PE (HP6017), or 
IgM PE (MHM-88) (all BioLegend).
Phenotyping of fresh lymphocytes was performed within 3 h 
of blood collection using 1  mL of ACD anticoagulated blood. 
Erythrocytes were lysed at 4°C for 10 min in 10 mL of ammonium-
chloride-potassium (ACK) buffer (Gibco) and washed before 
staining in FACS buffer as above using Panel 1.
All samples were acquired on an LSR II (BD). The same 
machine was used for all experiments with daily calibration with 
Cytometer Setup and Tracking beads (BD) to maximize compa-
rability between days. Rainbow Calibration Particles (BioLegend) 
were also used for cohort phenotyping to minimize batch-to-
batch variability. Data were analyzed using FlowJo Version 
10.8.0r1 (Treestar). In some cases for the CD32high populations, 
cell numbers were very low. To ensure accuracy in the phenotyp-
ing of this population, any populations where there were five or 
fewer events were excluded from further phenotyping analyses. 
(Of note, the overall phenotype of this population did not change 
if this threshold was changed to fewer than 25 or 50 events.)
For sorting experiments, thawed PBMCs or tonsillar cells 
were stained in R10 at 4°C using Live/Dead Near IR, CD32 
PE-Cy7, CD3 FITC and either (a) CD4 APC and CD14 VioBlue 
or (b) CD4 eFluor450. Cells were sorted using a Mo-Flo XDP into 
four CD3+CD4+ populations: CD32−, CD32low, CD32+CD14+, 
and CD32high cells.
cD4 isolation Using easysep Kit
Peripheral blood mononuclear cells were thawed as above. 
For Fc blocking experiments, this was split into two aliquots. 
One aliquot was treated for 10 min at room temperature with 
Human TruStain FcX (BioLegend) according to the manufac-
turer’s protocol while the other was left untreated. A fraction 
of each aliquot was removed for CD32 staining. The remainder 
was used for CD4 enrichment via negative selection with the 
EasySep Human CD4 Enrichment Kit (StemCell) per the manu-
facturer’s protocol. PBMCs or enriched CD4s were stained as 
above with Live/Dead Near IR, CD32 PE-Cy7, CD3 FITC, and 
CD4 eFluor450.
Measurement of hiV Dna
For measurement of HIV DNA in bulk CD4 T cells, CD4 T cells 
were enriched from cryopreserved PBMCs as above or using 
Dynabeads Untouched Human CD4 T Cell Enrichment kit 
(Invitrogen). DNA was extracted from PBMCs or enriched CD4 
T cells (using QIAamp Blood Mini Kit, Qiagen) and sorted CD4 
T cell subsets (using QIAamp DNA Micro Kit or Mini Kit, both 
Qiagen) for use as input for qPCR assays. Copies of HIV-1 DNA 
were quantified and normalized to number of input cells (as 
determined by albumin PCR), by a previously described assay 
(22, 23) with both qPCR assays performed in triplicate. For sorted 
populations, PCR reactions for both albumin and total HIV were 
performed in triplicate for the CD32− population and in duplicate 
for the remaining populations, except where otherwise noted. 
Negative sample wells were replaced with zeros when averaging 
replicate values.
Unspliced hiV-rna Transcript 
Quantitation
RNA was isolated using the Qiagen AllPrep DNA/RNA Mini kit 
as per the manufacturer’s recommendations with the addition 
of two on-column double DNase digestions. The RNA assay 
performed as previously described (6). Briefly, complementary 
DNA was subjected to two rounds of PCR using semi-nested 
primers. The first reaction was a 15-cycle endpoint reaction 
using MH535 (5′-AACTAGGGAACCCACTGCTTAAG-3′) and 
SL20 (5′-TCTCCTTCTAGCCTCCGCTAGTC-3′) primers at a 
concentration of 400 nM each. The second reaction was a 40-cycle 
quantitative reaction (forward primer 5′-TAAAGCTTGCCTTG 
AGTGCT, SL20 and the probe FAM—5′-AGTRGTGTGTG 
CCCGTCTGTTG-3′—BHQ-1; 330 nM each), performed using 
a Roche Lightcycler 480. The HIV standard was generated by 
in vitro transcribing the plasmid Sp5-NL4.3 (generously provided 
by the lab of D. Purcell) using the RiboMax Large Scale SP6 RNA 
production System (Promega). HIV RNA standards were diluted 
in 10  ng/µL uninfected PBMC RNA. Any background from 
wells without reverse transcriptase was subtracted from final 
measurements. HIV RNA copies were normalized to RNA weight 
measured via Nanodrop.
statistical analysis
Continuous variables were compared between groups using non-
parametric tests throughout. Where three groups were com-
pared, a Kruskal–Wallis test was used; pairwise comparisons 
were performed on all combinations of groups only if the overall 
test p-value was <0.05. Correlative analyses were performed 
using Spearman’s rank correlation. Time to viral rebound was 
FigUre 1 | Depletion of diverse populations of CD32-expressing CD4 T cells by negative bead selection due to the expression of non-T cell markers.  
(a) The frequency of CD32+CD3+CD4+ T cells when measured in peripheral blood mononuclear cells (PBMCs), or in CD4 T cells purified by negative bead selection, 
with and without Fc block prior. (B) Representative gating of data shown in panel (a). (c) Gating of three CD32-expressing populations based on differing levels of 
expression and CD14: CD32low, CD32+CD14+, and CD32high. (D) Heat-map showing the percentage expression of markers used in CD4 negative bead isolation kits 
on subsets of CD3+CD4+ T cells [defined in panel (c)]. Expression was measured by flow cytometry, and values are shown as the mean of three individual donors. 
(e) Percentage expression of CD11b, CD19, CD36, and CD20 on CD3+CD4+ subpopulations as shown in panel (D). Bar is shown at the mean.
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assessed as time from TI to the first of two consecutive VL meas-
urements >400 copies/mL (the limit of detection of the assay 
used at some trial sites). Individuals who did not rebound were 
censored at the date of the last VL measurement. Time to viral 
rebound was visualized with Kaplan–Meier curves stratified at 
the median and associations examined using Cox proportional 
hazard models. Analyses were performed using GraphPad 
Prism (GraphPad Software, La Jolla, CA, USA) version 6.0f or 
R version 3.2.2.
resUlTs anD DiscUssiOn
Depletion of cD32-expressing cD4 T cells 
by negative Bead selection due to the 
expression of non-T cell Markers
The experimental study of CD4 T cells frequently incorporates a 
commercial bead-based negative selection kit in the laboratory 
protocol to produce a purified population of CD4 T cells from 
FigUre 2 | Characterization of T cell receptor and immunoglobulin (Ig) expression on CD32highCD3+CD4+ T cells. (a) Expression of TCRαβ on CD32-expressing 
CD3+CD4+ T cell populations was measured by flow cytometry and is shown here as median fluorescence intensity. Bar is shown at the mean. (B) Histogram 
showing TCRαβ staining on CD32-expressing CD3+CD4+ T cell populations of one sample shown in panel (a). Fluorescence minus one (FMO) controls are shown 
as dashed lines and individual populations as solid lines. (c) Percentage expression of Ig was measured on CD3+CD4+CD32highCD20+ cells. Expression of IgD, IgG, 
and IgM is shown. Expression was measured by flow cytometry, and bar is shown at the mean. (D) Representative staining of data shown in panel (c).
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bulk PBMCs. We identified that CD32 expression on purified CD4 
T cells isolated by negative bead selection was consistently lower 
than in CD4 T cells in PBMCs. To test if the cell purification kits 
depleted CD32-expressing CD4 T cells, we compared frequencies 
of CD32+CD4 T cells before and after negative selection by flow 
cytometry. We found a significant decrease in CD32 expression 
after negative selection (Figures 1A,B), which was not prevented 
by pre-treatment with an Fc blocking reagent to control for non-
specific antibody binding (Figure 1A).
As these data suggested that CD32+CD4 T cells express other 
surface molecules specifically depleted by the negative selection 
kit (which does not contain anti-CD32 antibodies), we looked for 
co-expression with CD32 of a panel of lineage-defining markers 
used in CD4 T  cell selection kits from several manufacturers. 
These were as follows: CD8, CD11b, CD14, CD15, CD16, CD19, 
CD20, CD36, CD56, CD123, TCRγδ, and CD235a.
The monocyte marker, CD14, distinguished a separate popula-
tion of CD32+CD14+ cells. The remaining CD14−CD32+ cells could 
be divided into two distinct populations, CD32low and CD32high 
(Figure  1C). We therefore further characterized lineage marker 
expression in these four populations—CD32−, CD32low, CD32high, 
and CD32+CD14+ and found clear phenotypic differences, con-
sistent with four distinct cell populations (Figure 1D; Figure S1 
in Supplementary Material). CD32−CD4 T  cells did not express 
significant levels of any tested lineage markers. CD32+CD14+ 
cells all expressed CD11b (Figure  1E) and were found almost 
entirely within a monocyte-rich FSC/SSC region (Figure S2 in 
Supplementary Material), consistent with these cells being mono-
cytes despite high levels of CD3 expression. It is possible that these 
cells are monocytes which have acquired CD3 via trogocytosis. The 
CD32low population expressed high levels of CD36 (Figure 1E), a 
scavenger receptor typically found on platelets and monocytes in 
blood but which has also been reported on CD4 T cells interacting 
with platelets (24). The CD32high cells expressed high levels of CD19 
and CD20, traditional markers of B cells (Figure 1E; representative 
staining in Figures S1B,C in Supplementary Material).
We focused on further characterization of the CD32high popula-
tion, which has been reported to have the highest level of persistent 
HIV infection (11). As these cells also expressed CD3, CD4, CD19, 
and CD20, we were interested to see whether these cells expressed 
other markers associated with B or T cell lineage and function. To 
confirm that cells expressing CD3, CD4, and CD32 were T cells, 
we stained for TCRαβ expression. As we would expect for T cell 
populations, the CD32−, CD32low, and CD32high populations all 
expressed similar levels of TCRαβ, while the CD32+CD14+ cells 
expressed very little, consistent with this subpopulation being 
monocytes (Figures  2A,B). We examined the expression of 
IgG, IgD, and IgM on the CD32high cells. We found the CD32high 
TaBle 1 | Demographic and clinical characteristics of participants included in 
clinical studies.
heaTher (n = 20)a sParTac (n = 19)b
sex
•	Male 20 (100%) 5 (26%)
Age 33 (28–40.8) 27 (22–40)
country
•	UK 20 (100%) 4 (21%)
•	South Africa/Uganda 0 13 (68%)
•	Other 0 2 (11%)
Time between estimated date of  
seroconversion and antiretroviral  
therapy (ART) initiation (days)
41.5 (22.5–55.3) 109 (76–124)
Time of sampling (weeks since  
ART initiation)
52.5 (52.0–57.6) 47.9 (47.6–48.0)
Baseline CD4 T cell count (cells/μL) 514 (376–628) 634 (535–764)
Baseline HIV RNA (log10 copies/mL) 6.32 (4.55–6.76) 4.32 (3.68–4.95)
Demographic and clinical characteristics of participants included in clinical studies. 
Values given represent n (%) for categorical variables and median (interquartile range) 
for continuous variables.
aData from these individuals contribute to Figures 3A–E and 5A,C and Figures S5A–D, 
S6A, S9, and S10 in Supplementary Material.
bData from these individuals contribute to Figure 5 and Table S4 in Supplementary 
Material.
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population, which co-express CD20 and TCRαβ, expressed 
high levels of IgD and IgM, but not IgG, similar to a naïve B cell 
phenotype (25) (Figures 2C,D). These results, surprisingly, show 
that the CD32high population express both T and B cell phenotypic 
markers. While rare, CD20-expressing T cells populations have 
been described in healthy individuals and in a number of non-
malignant disease states (26–31). Of note, the cells we described 
differ from these reports which generally expressed CD20 but not 
CD19.
Other investigators noting CD3 and CD20 co-expression have 
attempted to determine if this finding might be artefactual and 
secondary to contamination, cell doublets, cryopreservation or 
cell separation techniques (26, 31). Accordingly, for all experi-
ments, cells were tightly gated on singlets (as shown in Figure 
S3A in Supplementary Material), to minimize the possibility of a 
doublet artefact in our data. Of note, performing a second dou-
blet exclusion step does not change the frequency or phenotype 
of these cells (Figure S3B in Supplementary Material). To exclude 
the possibility that this phenotype was an artefact of density gra-
dient separation or cryopreservation of PBMCs we stained fresh, 
whole blood from healthy donors and observed a similar pattern 
of CD32 and CD20 co-expression on CD3+CD4+ cells (Figure S4 
in Supplementary Material).
Overall, these results have clear implications for those 
exploring the findings of Descours et  al  (11) as negative bead 
isolation of CD4 T cells will not only reduce the overall number 
of CD32+CD3+CD4+ cells but also affect the composition of the 
overall CD32-expressing population.
cD32-expressing cD3+cD4+ cells Differ 
in Their expression of icrs and Memory 
Phenotype
We further explored the phenotype of CD32-expressing CD4+ pop-
ulations in individuals who commenced ART during PHI from the 
HEATHER (7) cohort. Key demographic and clinical characteristics 
are shown in Table 1. In these individuals, we studied both CD32low 
and CD32highCD3+CD4+ populations separately without using 
cell enrichment kits (representative gating shown in Figure  3A) 
and imposing a conservative lymphocyte gate to eliminate the 
CD32+CD14+ population (Figure S2 in Supplementary Material, 
with doublet exclusion as in Figure S3C in Supplementary Material).
The expression of the ICRs PD-1 and TIGIT has been reported 
to mark a population of CD3+CD4+ T  cells enriched for HIV 
DNA, although the fold enrichment in HIV DNA is substantially 
lower than described for CD32 (8, 9, 11). We found that in treated 
HIV+ individuals, the expression of PD-1, Tim-3, and TIGIT was 
elevated on CD32low CD3+CD4+ cells compared with their CD32− 
and CD32high counterparts (Figures 3B–D).
We compared the memory phenotype of CD32−, CD32low, and 
CD32high  CD3+CD4+ cell subsets during treated PHI. CD32lowCD4 
T cells had lower proportions of naïve and central memory (TCM) 
T cells than their CD32− counterparts. By contrast, transitional 
memory (TTM), effector memory (TEM), and TEMRA cells com-
prised a greater portion of the CD32low CD4 T cell pool than for 
CD32−CD4 T cells (Figure 3E), reflecting a more differentiated 
memory phenotype. By contrast, the CD32high population was 
largely comprised of cells which expressed CD45RA marking a 
naïve or TEMRA phenotype. It is interesting that central memory 
cells—the memory subset with the highest level of proviral 
DNA (9, 32)—were most common among CD32− cells and less 
frequent among both CD32low and CD32high cells. Furthermore, 
CD32high cells contained lower levels of PD-1, Tim-3, and TIGIT 
than CD32low cells suggesting that this may be a distinct popula-
tion of HIV-infected cells than those enriched ICR expressing 
populations (8, 9, 11).
The overall phenotype of these cells did not differ between par-
ticipant groups. This same pattern of ICR expression was observed 
before ART initiation (Figures S5A–C in Supplementary Material) 
and in healthy controls (Figures S5E–G in Supplementary 
Material), except for Tim-3 which was expressed at very low 
levels in CD4 T cells from controls. Similarly, these cells had the 
same memory phenotype before ART initiation (Figure S6A in 
Supplementary Material) and in healthy controls (Figure S6B 
in Supplementary Material). The distinct phenotype of CD32−, 
CD32low, and CD32high populations with regards to memory 
differentiation and ICR expression adds to the lineage marker 
evidence that these are distinct cellular populations and are found 
in healthy as well as HIV-infected individuals.
cD32high cD3+cD4+ T cells are activated 
and express high levels of hiV  
co-receptors
Among treated HIV-infected individuals (n =  19, Table S1 in 
Supplementary Material) CD32high CD3+CD4+ cells expressed 
markedly elevated levels of the activation marker HLA-DR 
compared with both other populations (Figure 3F; also shown 
at baseline in Figure S5D in Supplementary Material). In healthy 
controls, the expression of CCR5 and CXCR4, the co-receptors 
FigUre 3 | Continued
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FigUre 4 | HIV DNA quantification in sorted CD32-expressing CD3+CD4+ 
T cell populations. HIV DNA was quantified in sorted CD32−, CD32low, 
CD32+CD14+, and CD32high CD3+CD4+ T cell populations by qPCR (n = 9).  
(a) Shows the absolute quantification of these data and (B) shows the fold 
change relative to the CD32− population. Copies of HIV-1 DNA were quantified 
and normalized to number of input cells (as determined by albumin PCR).  
PCR reactions for both albumin and total HIV were performed in triplicate for 
the CD32− population and in duplicate for the remaining three populations.  
Data shown are averages of the replicates. Data points are colored by the 
individual from which the population was sorted. Where no signal was 
detectable for a given sorted population, this is shown as an open circle on the 
axis. For all of these undetectable populations, we could not determine if they 
were in fact negative for HIV DNA as the predicted level of infection (assuming 
equivalent level of infection to the CD32− fraction) was below the level of 
detection of our assay based on the available input cell equivalents.
FigUre 3 | CD32-expressing CD3+CD4+ cells differ in their expression of immune checkpoint receptors, the activation marker HLA-DR and HIV co-receptors,  
as well as their memory phenotype. Representative gating of CD32-expressing populations on CD4 T cells from an HIV+ individual is shown (top panel) in panel  
(a), relative to isotype control (bottom panel). CD32−, CD32low, and CD32highCD3+CD4+ T cell populations were compared with regards to their expression of 
programmed death receptor-1 (PD-1) (B), Tim-3 (c), TIGIT [(D); all n = 20], and HLA-DR [(F), n = 19]. For panel (F), four samples were excluded from the  
analysis of the CD32high population because there were five or fewer events. These same populations were compared with regards to their memory phenotype. 
The percentage of each population composed of naïve (CD45RA+CCR7+), central memory (TCM; CD45RA−CCR7+), transitional memory (TTM; CD45RA−CCR7−CD27+), 
effector memory (TEM; CD45RA−CCR7−CD27−), and TEMRA cells (CD45RA+CCR7−) was quantified by flow cytometry and is shown in panel (e) (n = 20). The 
comparisons are all shown in HIV+ individuals at 1 year following the initiation of antiretroviral therapy. The expression of HIV co-entry receptors CCR5 [(g); n = 6] 
and CXCR4 [(h); n = 5] was compared between CD32−, CD32low, and CD32highCD3+CD4+ T cell populations in healthy individuals. Throughout, a Kruskal–Wallis test 
was used to compare all three groups; pairwise comparisons were performed on all combinations of groups only if the overall test p-value was < 0.05; 
****p < 0.0001, ***p = 0.0001–0.001, **p = 0.001–0.01, *p = 0.01–0.05; for ease of interpretation if p ≥ 0.05 for any comparison this is not shown on these plots.
8
Martin et al. CD32-Expressing CD4 T Cells in HIV Infection
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 928
used by HIV for cellular entry, was increased on CD32highCD4 
T cells (Figures 3G,H). For CCR5, this was also observed on the 
CD32low population.
The HIV reservoir is considered to be comprised of resting 
CD4 T cells (9, 33–35). The elevated expression of the activation 
marker HLA-DR on CD32-expressing CD4 T  cells observed 
here is, therefore, potentially surprising. This finding is, how-
ever, consistent with two recent reports of elevated HLA-DR on 
bulk CD32+CD4 T cells from HIV-infected individuals (36, 37). 
Upregulation of CD32 expression on CD4 T cells with in vitro 
activation has been previously reported (15, 16), and it is possible 
that CD32 expression might mark a more activated subpopula-
tion of CD4 T  cells. This, rather than upregulation upon viral 
integration, could explain the increased frequency of CD32high 
cells observed during PHI (Figure 5A). Activated CD4 T cells 
are preferentially infected with HIV but rapidly die; the HIV 
reservoir is thought to form from cells that are infected while 
activated and then transition to a resting state (35, 38, 39), or 
while undergoing this transition (40). It is possible that with high 
cellular activation and high co-receptor expression, CD32high 
cells might be more susceptible to infection with HIV. Whether 
these cells are able to persist and contribute to long-term latency 
remains unclear.
hiV Dna in cD32-expressing cD3+cD4+ 
cell subsets
In initial experiments using negative selection beads, sort-
ing CD4 T  cells into CD32+ and CD32− fractions revealed an 
enrichment of HIV DNA in CD32+ cells from individuals who 
commenced ART  during PHI (clinical characteristics in Table 
S1 in Supplementary Material; sort strategy in Figure S7A in 
Supplementary Material) (41). As well as concerns detailed above 
over the impact of the negative selection beads, we also deter-
mined that for individuals with extremely low yields of sorted 
CD32+CD3+CD4+ cells, low cell inputs into the qPCR resulted 
in over-estimation of both albumin and HIV DNA (Figure S8 in 
Supplementary Material), which would need to be accounted for 
when comparing different cell populations. We, therefore, re-ana-
lyzed these data (Table S2 in Supplementary Material) accounting 
for assay cell input (which was lower for the CD32+ compared 
with the CD32− populations) and the number of positive qPCR 
replicates, and found that HIV DNA could still be detected within 
CD32+CD4 T cells, with some evidence for enrichment. All qPCR 
assays performed on sorted DNA included control wells without 
DNA template, which were consistently negative. To show that 
low inputs of HIV DNA did not give false positive signals, we 
diluted sorted CD32− HIV DNA such that each well contained 
<1 copy of HIV DNA and found no detectable signal in 21 wells 
(n = 3 individuals, 2 or 3 triplicate dilutions per individual; from 
experiments in Figure S8B in Supplementary Material).
FigUre 5 | The frequency of CD32-expressing CD3+CD4+ cells does not correlate with the size of the HIV reservoir. The percentage of CD32low (top panel) and 
CD32high (bottom panel) CD3+CD4+ cell populations is shown in panel (a) for HIV+ individuals with primary HIV infection pre-therapy (baseline; n = 19) and 1 year 
following antiretroviral therapy initiation (n = 39), as well as for controls (n = 10); groups were compared using a Kruskal–Wallis test. Bars indicate the median 
with the interquartile range. Panel (B) shows survival curves (Kaplan–Meier) of time to viral rebound >400 copies/mL based on the frequency of CD32low (top 
panel) and CD32high (bottom panel) CD3+CD4+ cells stratified at the median (n = 19). The relationship between measures of the HIV reservoir and percentage of 
CD32low (top panels) and CD32high (bottom panels) CD3+CD4+ cells in treated HIV+ individuals, shown in panel (c), was assessed using Spearman’s rank 
correlation. Left column shows total HIV DNA measured in isolated CD4 T cells (n = 39), the center column is total HIV DNA measured in peripheral blood 
mononuclear cells (PBMCs) (n = 20), and the right column shows cell-associated unspliced HIV RNA (n = 14); ****p < 0.0001, **p = 0.001–0.01, n.s. (not 
significant) indicates p ≥ 0.05.
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However, to negate the impact of negative selection beads on 
the CD32+ CD4 T cell population, all experiments were repeated 
sorting directly from bulk PBMCs. Cells from participants treated 
during PHI (Table S1 in Supplementary Material) were sorted 
directly into the four CD3+CD4+ populations (CD32−, CD32low, 
CD32+CD14+, and CD32high; Figure S7B in Supplementary 
Material) and HIV DNA quantified by qPCR. We were able to 
quantify HIV DNA in sorted CD32−, CD32low, CD32+CD14+, and 
CD32high CD3+CD4+ T cells from most individuals (Figure 4A). 
As expected, numbers of sorted cells from these populations 
were higher than for previous experiments using CD4 negative 
selection kits alleviating concerns regarding low input bias in 
the qPCR (Table S3 in Supplementary Material). We observed 
some degree of HIV DNA enrichment within CD32low cells from 
most individuals, although this was generally of low magnitude. 
CD32+CD14+ cells also contained detectable HIV DNA in 
most individuals. We also observed detectable HIV DNA in the 
CD32high population from seven of nine individuals sorted, which 
was enriched in four of these. The degree of enrichment varied 
substantially between individuals (Figure 4B).
Despite the technical challenges detailed above, we were 
confident that HIV DNA was detectable in all three populations 
of CD32-expressing CD4 T cells and that some enrichment in 
CD32high was observed in some individuals, although not in 
all. We have not, however, been able to replicate the magnitude 
of enrichment or the inter-individual consistency reported by 
Descours et  al. (11), despite starting with a similar number 
of PBMCs. Importantly, our study population of participants 
with treated PHI also differs from this previous study which 
included greater heterogeneity in regards to timing of ART 
initiation.
The Frequency of cD32-expressing 
cD3+cD4+ cells is not related to 
the Overall size of the hiV reservoir
To further explore the proposed association with CD32 
expression and the HIV reservoir, we studied additional indi-
viduals commencing ART during PHI from two clinical trials 
[SPARTAC (21) and HEATHER (7)]. Key demographic and 
clinical characteristics are shown in Table 1. The median time 
from estimated seroconversion to ART initiation was 74 days 
(interquartile range, IQR 36–114 days). Median baseline plasma 
viral load (pVL) was 4.94 log10(copies/mL) (IQR 4.09–6.52), 
and CD4 T cell count was 545 cells/μL (IQR 453–696). Clinical, 
immunological, and reservoir measures presented are at 
baseline (before the initiation of ART) and after 1 year of ART 
(median 48.1  weeks; IQR 47.9–52.9  weeks). Healthy controls 
[n =  10; 100% male; median age 34.5 (IQR 30.5–42.5) years] 
were included for comparison.
For participants on ART, the median percentage of CD32low 
cells was 5.38 (range 1.51–14.1%), and the rarer CD32high popula-
tion was 0.008% (range 0.002–0.02%). The frequency of CD32low 
cells did not differ from pre-therapy levels (median 5.55%, 
range 1.09–8.05%) or healthy controls (median 7.00%, range 
3.00–10.9%; Figure 5A; p = 0.26). Although unstimulated CD4 
T cells are not generally expected to express CD32 (10), we are not 
the first to observe low-level expression of CD32 on CD4 T cells 
from healthy controls (42). The frequency of CD32high cells was 
elevated during PHI relative to healthy controls (median 0.02%, 
range 0.01–0.09% versus median 0.007%, range 0.005–0.015%; 
p = 0.0004) but had decreased to similar levels (p < 0.0001) fol-
lowing 1 year of ART (Figure 5A).
Whether the percentage of CD32-expressing CD3+CD4+ 
cells predicted time to pVL rebound after ART TI was assessed 
in a subset of individuals after 48  weeks of suppressive ART 
(n = 19). In Cox models, we found no evidence to support such 
an association for either CD32low or CD32high cells (Figure 5B, 
Table S4 in Supplementary Material). Three individuals 
remained virologically suppressed at the end of follow-up 
after TI (median 197 weeks), all of whom expressed levels of 
CD32low below the median (Figure  5B). We did not observe 
any correlation between the percentage of CD32low or CD32high 
cells and the overall size of the HIV reservoir on ART as meas-
ured by several assays: total HIV DNA in negatively selected 
CD4 T cells, total HIV DNA in PBMCs, and the level of cell-
associated unspliced RNA (CA-usRNA) in PBMCs (Figure 5C; 
Figure S9 in Supplementary Material). We also measured HIV 
DNA in CD4 T cells before ART initiation and again observed 
no correlation between this and frequency of CD32-expressing 
populations (Figure S10 in Supplementary Material). In sum-
mary, we found no evidence that CD32 expression on CD4 
T cells is a surrogate of the total reservoir size as measured by 
HIV DNA, CA-usRNA or time to viral rebound. This is likely 
to be not just because CD32high cells are rare but that, even if 
enriched, a large part of the HIV reservoir is contained in other 
cell types.
cOnclUsiOn
We have identified three distinct populations of CD32-expres-
sing CD3+CD4+ T cells that differ in regards to their expression 
of lineage markers, ICRs, HLA-DR, and their memory pheno-
type. Our findings have implications for others studying these 
cells—particularly our finding that negative bead isolation of 
CD4 T  cells will deplete a major fraction of CD32-expressing 
cells due to their expression of non-T  cell markers. We have 
also shown that some CD32-expressing CD3+CD4+ cells also 
express CD14 and have a phenotype that suggests that these cells 
are monocytes. Efforts to ensure that these are excluded from 
analyses (which can be achieved with stringent gating) will be 
necessary in future studies.
The CD32high population is of particular interest because of 
the previously reported high level of HIV DNA enrichment. The 
surface co-expression of both B and T cell markers is unusual, 
but has been previously reported (26–31), and further study into 
the biology of this population is warranted. In the absence of this 
functional characterization we are cautious in drawing any con-
clusions about the origin of these cells. Possibilities include that 
this phenotype is the result of a functional interaction between 
B  cells and CD4 T  cells, or represents an unusual lymphocyte 
with the capability to express markers of both lineages. With high 
levels of activation and HIV co-receptor expression it is possible 
that this population may be preferentially infected with HIV, 
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although due to the rarity of this population we have not been 
able to directly test this.
We were able to identify HIV DNA in CD32−, CD32low, 
CD32+CD14+, and CD32high cells. Although cautious about the 
conclusions that can be drawn from our data, we found evidence 
for some degree of enrichment of HIV DNA in CD32-expressing 
populations in some individuals, although we were not able to 
replicate the magnitude of enrichment previously reported. One 
possible explanation is that unlike Descours et al. (11), we stud-
ied only individuals who commenced ART during PHI, when 
the reservoir size is smaller (18, 19, 43, 44), and it is possible 
that the distribution and dynamics of reservoir formation and 
decay may also differ. We also highlight some of the technical 
challenges in quantifying exact levels of HIV DNA in rare cell 
populations which will need to be considered in future stud-
ies of the reservoir. Even if CD32-expressing CD4 T  cells are 
enriched for HIV DNA in a given individual, it is likely that a 
large part of the reservoir is contained outside of this population. 
Supporting this, we found no evidence that CD32 expression on 
CD4 T cells is a surrogate of the total reservoir size as measured 
by HIV DNA, CA-usRNA or time to viral rebound. Overall, our 
data suggest that CD32 is not a specific marker of the reservoir 
but might identify a population of HIV enriched cells in a subset 
of patients.
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